SOPHiA GENETICS (SOPH) CLO sells 5,105 shares to cover RSU taxes

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 5,105 Ordinary Shares of SOPH in early April 2026. The sales, at weighted average prices of about $4.86–$4.87 per share, were made in the open market to cover tax withholding obligations from recently vested restricted stock units.

According to the disclosure, these transactions on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After the sales, Van Well continues to hold more than 350,000 Ordinary Shares directly.

Insights

Insider transactions analyst

Pre-planned insider sales to cover taxes, with sizable holdings retained.

Daan Van Well, Chief Legal Officer of SOPHiA GENETICS SA, sold 5,105 Ordinary Shares in two open-market transactions at weighted average prices around $4.86 per share. Footnotes state the purpose was to satisfy tax withholding obligations from RSU vesting.

The transactions were executed under a pre-established Rule 10b5-1 trading plan, which means the timing was set in advance rather than chosen opportunistically. Van Well still directly owns more than 350,000 shares after these sales, indicating he retains substantial equity exposure.

Because these sales are tax-related, pre-planned, and represent a small portion of the reported holdings, they appear to be routine administrative activity rather than a strong signal about management’s view of the company’s prospects.

Insider Trade Summary 10b5-1

Net Seller: 5,105 shares ($24,818)

Net Sell 2 txns

Insider Van Well Daan

Role Chief Legal Officer

Sold 5,105 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,400	$4.8674	$12K
Sale	Ordinary Shares	2,705	$4.8562	$13K

Holdings After Transaction: Ordinary Shares — 353,669 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.685 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.945, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold April 6, 2026: 2,705 shares at $4.8562 Shares sold April 7, 2026: 2,400 shares at $4.8674 Total shares sold: 5,105 shares +3 more

6 metrics

Shares sold April 6, 2026 2,705 shares at $4.8562 Open-market sale of Ordinary Shares

Shares sold April 7, 2026 2,400 shares at $4.8674 Open-market sale of Ordinary Shares

Total shares sold 5,105 shares Aggregate of April 6–7, 2026 sales

Holdings after April 7 sale 353,669 shares Direct ownership following transactions

Price range April 6 $4.77–$4.945 Weighted average price with intra-day range

Price range April 7 $4.685–$4.95 Weighted average price with intra-day range

Key Terms

Rule 10b5-1 trading plan, tax withholding obligations, restricted stock units, weighted average price

4 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding obligations financial

"sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units"

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Well Daan

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/06/2026		S		2,705(1)	D	$4.8562(2)	356,069	D
Ordinary Shares	04/07/2026		S		2,400(1)	D	$4.8674(3)	353,669	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.685 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.945, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did SOPHiA GENETICS (SOPH) report for Daan Van Well?

SOPHiA GENETICS reported that Chief Legal Officer Daan Van Well sold a total of 5,105 Ordinary Shares in two open-market transactions. The sales occurred on April 6 and 7, 2026 at weighted average prices of about $4.86–$4.87 per share.

Why did SOPHiA GENETICS Chief Legal Officer sell 5,105 shares of SOPH stock?

The filing states the 5,105 shares sold by Daan Van Well were to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026. This makes the transactions administrative, linked to compensation, rather than discretionary portfolio trades.

Were the SOPH insider share sales by Daan Van Well made under a Rule 10b5-1 plan?

Yes. The disclosure explains that the sales by Daan Van Well were executed under a pre-established Rule 10b5-1 trading plan. Such plans schedule trades in advance, so the timing of these sales does not reflect day-to-day market decisions by the insider.

How many SOPHiA GENETICS shares does Daan Van Well hold after these transactions?

After the reported sales, Daan Van Well directly holds more than 350,000 Ordinary Shares of SOPHiA GENETICS. The Form 4 shows post-transaction ownership of 356,069 shares after the April 6 sale and 353,669 shares after the April 7 sale.

At what prices were the SOPH shares sold by Daan Van Well in April 2026?

The Form 4 reports weighted average sale prices of about $4.8562 per share on April 6, 2026 and $4.8674 per share on April 7, 2026. Footnotes add that actual trade prices ranged roughly from $4.685 to $4.95 per share.